Display options
Cite
Guzman JD, Evangelopoulos D, Gupta A, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open. 2013;3(6)doi: 10.1136/bmjopen-2013-002672.
Guzman, J. D., Evangelopoulos, D., Gupta, A., Birchall, K., Mwaigwisya, S., Saxty, B., McHugh, T. D., Gibbons, S., Malkinson, J., & Bhakta, S. (2013). Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ open, 3(6), . https://doi.org/10.1136/bmjopen-2013-002672
Guzman, Juan D, et al. "Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay." BMJ open vol. 3,6 (2013). doi: https://doi.org/10.1136/bmjopen-2013-002672
Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, McHugh TD, Gibbons S, Malkinson J, Bhakta S. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open. 2013 Jun 20;3(6). doi: 10.1136/bmjopen-2013-002672. PMID: 23794563; PMCID: PMC3693423.
Copy Download .nbib Format: NLM
Share it on

BMJ Open. 2013 Jun 20;3(6). doi: 10.1136/bmjopen-2013-002672.

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay.

BMJ open

Juan D Guzman, Dimitrios Evangelopoulos, Antima Gupta, Kristian Birchall, Solomon Mwaigwisya, Barbara Saxty, Timothy D McHugh, Simon Gibbons, John Malkinson, Sanjib Bhakta

Affiliations

  1. Department of Biological Sciences, Mycobacteria Research Laboratory, Institute of Structural and Molecular Biology, Birkbeck, University of London, London, UK.

PMID: 23794563 PMCID: PMC3693423 DOI: 10.1136/bmjopen-2013-002672

Abstract

OBJECTIVES: Lead antituberculosis (anti-TB) molecules with novel mechanisms of action are urgently required to fuel the anti-TB drug discovery pipeline. The aim of this study was to validate the use of the high-throughput spot culture growth inhibition (HT-SPOTi) assay for screening libraries of compounds against Mycobacterium tuberculosis and to study the inhibitory effect of ibuprofen (IBP) and the other 2-arylpropanoic acids on the growth inhibition of M tuberculosis and other mycobacterial species.

METHODS: The HT-SPOTi method was validated not only with known drugs but also with a library of 47 confirmed anti-TB active compounds published in the ChEMBL database. Three over-the-counter non-steroidal anti-inflammatory drugs were also included in the screening. The 2-arylpropanoic acids, including IBP, were comprehensively evaluated against phenotypically and physiologically different strains of mycobacteria, and their cytotoxicity was determined against murine RAW264.7 macrophages. Furthermore, a comparative bioinformatic analysis was employed to propose a potential mycobacterial target.

RESULTS: IBP showed antitubercular properties while carprofen was the most potent among the 2-arylpropanoic class. A 3,5-dinitro-IBP derivative was found to be more potent than IBP but equally selective. Other synthetic derivatives of IBP were less active, and the free carboxylic acid of IBP seems to be essential for its anti-TB activity. IBP, carprofen and the 3,5-dinitro-IBP derivative exhibited activity against multidrug-resistant isolates and stationary phase bacilli. On the basis of the human targets of the 2-arylpropanoic analgesics, the protein initiation factor infB (Rv2839c) of M tuberculosis was proposed as a potential molecular target.

CONCLUSIONS: The HT-SPOTi method can be employed reliably and reproducibly to screen the antimicrobial potency of different compounds. IBP demonstrated specific antitubercular activity, while carprofen was the most selective agent among the 2-arylpropanoic class. Activity against stationary phase bacilli and multidrug-resistant isolates permits us to speculate a novel mechanism of antimycobacterial action. Further medicinal chemistry and target elucidation studies could potentially lead to new therapies against TB.

Keywords: BACTERIOLOGY; NSAIDs; Whole Cell Phenotypic Screening

References

  1. J Clin Pathol. 1998 Mar;51(3):220-4 - PubMed
  2. Biochem Pharmacol. 1999 Feb 1;57(3):313-20 - PubMed
  3. Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19 - PubMed
  4. J Pharmacol Exp Ther. 2003 Sep;306(3):1086-91 - PubMed
  5. Brain Res Mol Brain Res. 1997 Oct 15;50(1-2):107-12 - PubMed
  6. J Am Vet Med Assoc. 1997 May 15;210(10):1493-8 - PubMed
  7. Brain Res Brain Res Rev. 2005 Apr;48(2):400-8 - PubMed
  8. Am J Respir Crit Care Med. 2000 Jan;161(1):192-9 - PubMed
  9. Lancet. 2010 May 22;375(9728):1830-43 - PubMed
  10. Int J Antimicrob Agents. 2010 Jun;35(6):524-6 - PubMed
  11. J Vet Pharmacol Ther. 1994 Dec;17(6):447-54 - PubMed
  12. FEMS Microbiol Lett. 1998 Jan 1;158(1):139-45 - PubMed
  13. Res Vet Sci. 1996 Mar;60(2):144-51 - PubMed
  14. Clin Cancer Res. 2005 Feb 15;11(4):1618-28 - PubMed
  15. PLoS One. 2009 Jun 29;4(6):e6077 - PubMed
  16. J Chem Inf Model. 2006 May-Jun;46(3):1060-8 - PubMed
  17. Nature. 2007 Aug 9;448(7154):645-6 - PubMed
  18. J Exp Med. 2004 May 3;199(9):1191-9 - PubMed
  19. PLoS One. 2010 Sep 09;5(9): - PubMed
  20. J Pharmacol Exp Ther. 2011 Jun;337(3):876-86 - PubMed
  21. Biochem Pharmacol. 2002 Feb 1;63(3):343-7 - PubMed
  22. Future Med Chem. 2011 Sep;3(11):1413-26 - PubMed
  23. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1152-4 - PubMed
  24. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11 - PubMed
  25. Ann Emerg Med. 1990 Jun;19(6):657-62 - PubMed
  26. Tuberculosis (Edinb). 2011 Jan;91(1):1-7 - PubMed
  27. Oman Med J. 2010 Jul;25(3):155-1661 - PubMed
  28. Bioorg Med Chem. 2007 May 15;15(10):3579-86 - PubMed
  29. EMBO J. 2000 Oct 2;19(19):5233-40 - PubMed
  30. J Antimicrob Chemother. 2010 Oct;65(10):2101-7 - PubMed
  31. Lett Appl Microbiol. 1995 Feb;20(2):82-4 - PubMed
  32. Clin Exp Immunol. 2002 May;128(2):229-37 - PubMed
  33. Cell Mol Life Sci. 2007 Jun;64(11):1403-18 - PubMed
  34. J Bacteriol. 1996 Aug;178(15):4484-92 - PubMed
  35. Eur J Biochem. 2000 Sep;267(17):5421-6 - PubMed
  36. Ann Emerg Med. 1986 Nov;15(11):1308-13 - PubMed
  37. J Clin Microbiol. 2007 Aug;45(8):2662-8 - PubMed
  38. Clin Pharmacol Ther. 1989 May;45(5):500-5 - PubMed
  39. Colloids Surf B Biointerfaces. 2005 Oct 10;45(2):108-11 - PubMed
  40. Tuberculosis (Edinb). 2009 Jul;89(4):310-6 - PubMed
  41. Methods Mol Biol. 2010;642:193-201 - PubMed
  42. J Antimicrob Chemother. 2007 Feb;59(2):313-6 - PubMed
  43. Mol Microbiol. 2006 Jan;59(1):181-92 - PubMed
  44. J Antimicrob Chemother. 2012 Jun;67(6):1380-91 - PubMed
  45. Antimicrob Agents Chemother. 2012 Aug;56(8):4140-5 - PubMed

Publication Types

Grant support